EUVIMEDObjevte EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

Catarina Serrão iD, Filipa Dourado Sotero iD, Linda Azevedo Kauppila iD, Isabel Pavão Martins iD

Headache: The Journal of Head and Face Pain · 2026-01 · 66 (1) · 336-340

DOI: 10.1111/head.15066 ↗

At a glance

Fallbericht in Headache: The Journal of Head and Face Pain, published online on 2025-10-03. Written by Catarina Serrão and 3 co-authors. Institution: Department of Neurosciences and Mental Health, Hospital de Santa Maria, ULS Santa Maria, Lisbon, Portugal. Major MEDLINE topics: Calcitonin Gene-Related Peptide Receptor Antagonists, Cluster Headache. Cited 3 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an oral, small‐molecule, CGRP receptor antagonist, which is approved for the preventive treatment of migraine. Here, we describe four case reports of CH (two episodic CH and two chronic CH), unresponsive to previous prophylactic treatments, who responded to daily atogepant (60 mg). Chronic CH cases were refractory to subcutaneous galcanezumab. In one case, a reduction to atogepant (30 mg daily) resulted in recurrence of headache attacks, which subsided on reintroduction of the initial dose. No serious adverse effects were reported. Despite the limited number of cases and the open retrospective design, our case series suggests atogepant as a possible prophylactic treatment for CH. Further research on CGRP signaling in CH and the implementation of well‐designed clinical trials are necessary.

Subjects

MeSH terms (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsCluster HeadacheHumansCalcitonin Gene-Related Peptide

Author keywords

CGRPatogepantcluster headachepreventive treatmentrefractory

Substances

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Department of Neurosciences and Mental Health, Hospital de Santa Maria, ULS Santa Maria, Lisbon, Portugal.
  • Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • CNS-Campus Neurológico, Torres Vedras, Portugal.
  • Hospital CUF Tejo, Lisbon, Portugal.

ORCID profiles: Catarina Serrão, Filipa Dourado Sotero, Linda Azevedo Kauppila, Isabel Pavão Martins

Cite

APA

Serrão, C., Sotero, F. D., Kauppila, L. A., & Martins, I. P. (2026). Can atogepant be a preventive treatment for cluster headache?—Insights from a case series. Headache: The Journal of Head and Face Pain, 66(1), 336-340. https://doi.org/10.1111/head.15066

Vancouver

Serrão C, Sotero FD, Kauppila LA, Martins IP. Can atogepant be a preventive treatment for cluster headache?—Insights from a case series. Headache: The Journal of Head and Face Pain. 2026;66(1):336-340. doi:10.1111/head.15066

BibTeX
@article{Serro2026,
  author = {Serrão, Catarina and Sotero, Filipa Dourado and Kauppila, Linda Azevedo and Martins, Isabel Pavão},
  title = {Can atogepant be a preventive treatment for cluster headache?—Insights from a case series},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {1},
  pages = {336--340},
  doi = {10.1111/head.15066}
}
Start for free →